An orally active and very potent antagonist of androgen receptor (AR); Second-generation of antiandrogen for the treatment of advanced prostate cancer; highly recommended tool in AR research.
References: online
C Tran et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324 (5928), 787-790. [online]
C Harrison. Anticancer drugs: New approaches to anti-androgen activities. Nature Reviews Drug Discovery 2009, 8, 452-453. [online]
CJ Hoimes and WK Kelley. Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol. 2010, 2(2), 107–123. [online]
G Di Lorenzo et al. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010, 70(8), 983-1000.
N Sharifi. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. Exp. Opin. Invest. Drugs 2010, 19(7), 837-846.
HI Scher et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375(9724), 1437-1446.
Y Chen et al. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2009, 10(10), 981-991.
Chemical Name: 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methyl-Benzamide